Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases

Lade...
Vorschaubild
Dateien
Zu diesem Dokument gibt es keine Dateien.
Datum
2018
Autor:innen
Berger, Nathan A
Besson, Valerie C
Boulares, A Hamid
Chiarugi, Alberto
Clark, Robert S
Curtin, Nicola J.
Cuzzocrea, Salvatore
Dawson, Ted M
Szabo, Csaba
et al.
Herausgeber:innen
Kontakt
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
DOI (zitierfähiger Link)
ArXiv-ID
Internationale Patentnummer
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Open Access Green
Sammlungen
Core Facility der Universität Konstanz
Gesperrt bis
Titel in einer weiteren Sprache
Forschungsvorhaben
Organisationseinheiten
Zeitschriftenheft
Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published
Erschienen in
British journal of pharmacology. 2018, 175(2), pp. 192-222. ISSN 0366-0826. eISSN 1476-5381. Available under: doi: 10.1111/bph.13748
Zusammenfassung

The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors.

Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
570 Biowissenschaften, Biologie
Schlagwörter
Konferenz
Rezension
undefined / . - undefined, undefined
Zitieren
ISO 690BERGER, Nathan A, Valerie C BESSON, A Hamid BOULARES, Alexander BÜRKLE, Alberto CHIARUGI, Robert S CLARK, Nicola J. CURTIN, Salvatore CUZZOCREA, Ted M DAWSON, Csaba SZABO, 2018. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. In: British journal of pharmacology. 2018, 175(2), pp. 192-222. ISSN 0366-0826. eISSN 1476-5381. Available under: doi: 10.1111/bph.13748
BibTex
@article{Berger2018Oppor-41708,
  year={2018},
  doi={10.1111/bph.13748},
  title={Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases},
  number={2},
  volume={175},
  issn={0366-0826},
  journal={British journal of pharmacology},
  pages={192--222},
  author={Berger, Nathan A and Besson, Valerie C and Boulares, A Hamid and Bürkle, Alexander and Chiarugi, Alberto and Clark, Robert S and Curtin, Nicola J. and Cuzzocrea, Salvatore and Dawson, Ted M and Szabo, Csaba}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/41708">
    <dc:contributor>Cuzzocrea, Salvatore</dc:contributor>
    <dc:creator>Dawson, Ted M</dc:creator>
    <dc:language>eng</dc:language>
    <dc:contributor>Dawson, Ted M</dc:contributor>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/41708"/>
    <dc:contributor>Boulares, A Hamid</dc:contributor>
    <dcterms:issued>2018</dcterms:issued>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2018-03-07T09:55:25Z</dc:date>
    <dc:contributor>Clark, Robert S</dc:contributor>
    <dc:rights>terms-of-use</dc:rights>
    <dc:creator>Chiarugi, Alberto</dc:creator>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Bürkle, Alexander</dc:creator>
    <dc:contributor>Berger, Nathan A</dc:contributor>
    <dc:contributor>Curtin, Nicola J.</dc:contributor>
    <dcterms:abstract xml:lang="eng">The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors.</dcterms:abstract>
    <dc:creator>Cuzzocrea, Salvatore</dc:creator>
    <dc:contributor>Bürkle, Alexander</dc:contributor>
    <dc:contributor>Besson, Valerie C</dc:contributor>
    <dc:contributor>Szabo, Csaba</dc:contributor>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/41708/1/Berger_2-uyiw5z27na2s1.pdf"/>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2018-03-07T09:55:25Z</dcterms:available>
    <dc:creator>Clark, Robert S</dc:creator>
    <dc:creator>Curtin, Nicola J.</dc:creator>
    <dc:creator>Besson, Valerie C</dc:creator>
    <dcterms:title>Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases</dcterms:title>
    <dc:creator>Berger, Nathan A</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Szabo, Csaba</dc:creator>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Boulares, A Hamid</dc:creator>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/41708/1/Berger_2-uyiw5z27na2s1.pdf"/>
    <dc:contributor>Chiarugi, Alberto</dc:contributor>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
  </rdf:Description>
</rdf:RDF>
Interner Vermerk
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Kontakt
URL der Originalveröffentl.
Prüfdatum der URL
Prüfungsdatum der Dissertation
Finanzierungsart
Kommentar zur Publikation
Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet
Ja
Diese Publikation teilen